The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Open accessAbstract
This review is focused on different subsets of T cells: CD4 and CD8, memory and effector functions, and their role in CAR-T therapy––a cellular adoptive immunotherapy with T cells expressing chimeric antigen receptor. The CAR-T cells recognize tumor antigens and induce cytotoxic activities against tumor cells. Recently, differences in T cell functions and the role of memory and effector T cells were shown to be important in CAR-T cell immunotherapy. The CD4+ subsets (Th1, Th2, Th9, Th17, Th22, Treg, and Tfh) and CD8+ memory and effector subsets differ in extra-cellular (CD25, CD45RO, CD45RA, CCR-7, L-Selectin [CD62L], etc.); intracellular markers (FOXP3); epigenetic and genetic programs; and metabolic pathways (catabolic or anabolic); and these differences can be modulated to improve CAR-T therapy. In addition, CD4+ Treg cells suppress the efficacy of CAR-T cell therapy, and different approaches to overcome this suppression are discussed in this review. Thus, next-generation CAR-T immunotherapy can be improved, based on our knowledge of T cell subsets functions, differentiation, proliferation, and signaling pathways to generate more active CAR-T cells against tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michalek, R. D., Gerriets, V. A., Jacobs, S. R., Macintyre, A. N., MacIver, N. J., Mason, E. F., Sullivan, S. A., Nichols, A. G., & Rathmell, J. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003613 · Cited by 2,091
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Fueling Immunity: Insights into Metabolism and Lymphocyte Function
Pearce, E. L., Poffenberger, M. C., Chang, C.-H., & Jones, R. G. (2013) · Science · doi:10.1126/science.1242454 · Cited by 1,363 · cited 5×
“In the murine asthma model, stimulation of Treg metabolic player, AMP-activated protein kinase, was sufficient to decrease Glut1 and increase Treg generation [25].”
BackgroundInfluentialKawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Raphael, I., Nalawade, S., Eagar, T. N., & Forsthuber, T. G. (2015) · Cytokine · doi:10.1016/j.cyto.2014.09.011 · Cited by 1,160
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Murai, M., Turovskaya, O., Kim, G., Madan, R., Karp, C. L., Cheroutre, H., & Kronenberg, M. (2009) · Nature Immunology · doi:10.1038/ni.1791 · Cited by 850
Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 824
Xu, Y., Zhang, M., Ramos, C. A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C. J., Gee, A. P., Heslop, H. E., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552174 · Cited by 744
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
Ahmadzadeh, M., & Rosenberg, S. A. (2006) · Blood · doi:10.1182/blood-2005-06-2399 · Cited by 632
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Paths to stemness: building the ultimate antitumour T cell
Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3322 · Cited by 599
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Metabolic switching and fuel choice during T‐cell differentiation and memory development
van der Windt, G. J. W., & Pearce, E. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01150.x · Cited by 563
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus
Feng, Y., Arvey, A., Chinen, T., van der Veeken, J., Gasteiger, G., & Rudensky, A. Y. (2014) · Cell · doi:10.1016/j.cell.2014.07.031 · Cited by 422
Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy
Sukumar, M., Liu, J., Mehta, G. U., Patel, S. J., Roychoudhuri, R., Crompton, J. G., Klebanoff, C. A., Ji, Y., Li, P., Yu, Z., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.11.002 · Cited by 388
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 353
Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation
The Immunological Genome Project Consortium, Best, J. A., Blair, D. A., Knell, J., Yang, E., Mayya, V., Doedens, A., Dustin, M. L., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2536 · Cited by 348
Rosenblum, M. D., Way, S. S., & Abbas, A. K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.1 · Cited by 348
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy?
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827806e6 · Cited by 277
Yao, X., Ahmadzadeh, M., Lu, Y.-C., Liewehr, D. J., Dudley, M. E., Liu, F., Schrump, D. S., Steinberg, S. M., Rosenberg, S. A., & Robbins, P. F. (2012) · Blood · doi:10.1182/blood-2011-10-386482 · Cited by 206
CAR T Cells for Solid Tumors: Armed and Ready to Go?
Kakarla, S., & Gottschalk, S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000032 · Cited by 190
Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 187
Chmielewski, M. M., & Abken, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1202-z · Cited by 157
Gross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 149
Kofler, D. M., Chmielewski, M. M., Rappl, G., Hombach, A., Riët, T., Schmidt, A., Hombach, A. A., Wendtner, C., & Abken, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.9 · Cited by 141
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M. H., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26286 · Cited by 134
Moeller, M., Haynes, N. M., Kershaw, M. H., Jackson, J. T., Teng, M. W. L., Street, S. E. A., Cerruti, L., Jane, S. M., Trapani, J. A., Smyth, M. J., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4906 · Cited by 122
Gargett, T., & Brown, M. P. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2014.12.002 · Cited by 115
Liadi, I., Singh, H., Romain, G., Rey-Villamizar, N., Merouane, A., Adolacion, J. R. T., Kebriaei, P., Huls, H. M., Qiu, P., Roysam, B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0195 · Cited by 102
Yang, S., Ji, Y., Gattinoni, L., Zhang, L., Yu, Z., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1378-2 · Cited by 95
Zediak, V. P., Johnnidis, J. B., Wherry, E. J., & Berger, S. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003741 · Cited by 80
Condomines, M., Arnason, J. E., Benjamin, R., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130518 · Cited by 71
Turtle, C. J., Berger, C., Sommermeyer, D., Hanafi, L., Pender, B., Robinson, E. M., Melville, K., Budiarto, T. M., Steevens, N. N., Chaney, C. N., et al. (2015) · Blood · doi:10.1182/blood.v126.23.184.184 · Cited by 71
Turtle, C. J., Hanafi, L., Berger, C., Sommermeyer, D., Pender, B., Robinson, E. M., Melville, K., Budiarto, T. M., Steevens, N. N., Chaney, C. N., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3773.3773 · Cited by 56
Adoptive Therapy with CAR Redirected T Cells: The Challenges In Targeting Solid Tumors
Abken, H. (2015) · Immunotherapy · doi:10.2217/imt.15.15 · Cited by 53
The Emergence of T-Bodies/CAR T Cells
Eshhar, Z., Waks, T., & Gross, G. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000027 · Cited by 51
Cheadle, E. J., Sheard, V., Rothwell, D. G., Bridgeman, J. S., Ashton, G., Hanson, V., Mansoor, A. W., Hawkins, R. E., & Gilham, D. E. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302148 · Cited by 48
Lamers, C. H. J., van Steenbergen‐Langeveld, S., van Brakel, M., Ruijven, C. M. G.-V., van Elzakker, P., Krimpen, B. A. V., Sleijfer, S., & Debets, R. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.051 · Cited by 32
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
Abate‐Daga, D., Rosenberg, S. A., & Morgan, R. A. (2014) · OncoImmunology · doi:10.4161/onci.29194 · Cited by 11
Cited by
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
Yu, H., Lin, L., Zhang, Z., Zhang, H., & Hu, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00312-6 · Cited by 2,135
Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01960 · Cited by 1,364
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health
Mazziotta, C., Tognon, M., Martini, F., Torreggiani, E., & Rotondo, J. C. (2023) · Cells · doi:10.3390/cells12010184 · Cited by 889
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Metadata
- Authors
- Golubovskaya, V., & Wu, L.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2016-03-15
- Volume
- 8
- Issue
- 3
- Pages
- 36
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2297219066
- Cited by
- 577
- References
- 48
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.